BTK and B-cell chronic lymphocytic leukemia: The first-generation BTK inhibitor, ibrutinib, rapidly became the standard of care for treating patients with certain subtypes of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL) (21–24).